These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 9242451

  • 1. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
    Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K.
    Cancer Res; 1997 Aug 01; 57(15):3208-13. PubMed ID: 9242451
    [Abstract] [Full Text] [Related]

  • 2. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K.
    Cancer Res; 1994 Apr 01; 54(7):1702-6. PubMed ID: 8137285
    [Abstract] [Full Text] [Related]

  • 3. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
    Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, Wu-Wong JR, Frost D, Sham H, Rosenberg SH, Ng SC.
    Cancer Res; 2001 Jul 15; 61(14):5480-5. PubMed ID: 11454695
    [Abstract] [Full Text] [Related]

  • 4. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
    Chang JY, Chang CY, Kuo CC, Chen LT, Wein YS, Kuo YH.
    Mol Pharmacol; 2004 Jan 15; 65(1):77-84. PubMed ID: 14722239
    [Abstract] [Full Text] [Related]

  • 5. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC.
    Clin Cancer Res; 2005 Aug 15; 11(16):6002-11. PubMed ID: 16115945
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
    Zuse A, Schmidt P, Baasner S, Böhm KJ, Müller K, Gerlach M, Günther EG, Unger E, Prinz H.
    J Med Chem; 2006 Dec 28; 49(26):7816-25. PubMed ID: 17181164
    [Abstract] [Full Text] [Related]

  • 8. Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis.
    Bowdon BJ, Waud WR, Wheeler GP, Hain R, Dansby L, Temple C.
    Cancer Res; 1987 Mar 15; 47(6):1621-6. PubMed ID: 3815360
    [Abstract] [Full Text] [Related]

  • 9. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY.
    J Pharmacol Exp Ther; 2007 Oct 15; 323(1):398-405. PubMed ID: 17660383
    [Abstract] [Full Text] [Related]

  • 10. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
    Beckers T, Reissmann T, Schmidt M, Burger AM, Fiebig HH, Vanhoefer U, Pongratz H, Hufsky H, Hockemeyer J, Frieser M, Mahboobi S.
    Cancer Res; 2002 Jun 01; 62(11):3113-9. PubMed ID: 12036922
    [Abstract] [Full Text] [Related]

  • 11. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
    Gupta K, Bishop J, Peck A, Brown J, Wilson L, Panda D.
    Biochemistry; 2004 Jun 01; 43(21):6645-55. PubMed ID: 15157098
    [Abstract] [Full Text] [Related]

  • 12. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
    Perchellet EM, Ladesich JB, Magill MJ, Chen Y, Hua DH, Perchellet JP.
    Anticancer Drugs; 1999 Jun 01; 10(5):489-504. PubMed ID: 10477169
    [Abstract] [Full Text] [Related]

  • 13. Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines.
    Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido M, Saijo N.
    Jpn J Cancer Res; 1998 Sep 01; 89(9):954-62. PubMed ID: 9818032
    [Abstract] [Full Text] [Related]

  • 14. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
    Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, Bartlett JB, Schafer PH, Payvandi F.
    Cancer Res; 2006 Jan 15; 66(2):951-9. PubMed ID: 16424030
    [Abstract] [Full Text] [Related]

  • 15. Identification and characterization of A-105972, an antineoplastic agent.
    Wu-Wong JR, Alder JD, Alder L, Burns DJ, Han EK, Credo B, Tahir SK, Dayton BD, Ewing PJ, Chiou WJ.
    Cancer Res; 2001 Feb 15; 61(4):1486-92. PubMed ID: 11245455
    [Abstract] [Full Text] [Related]

  • 16. Antiproliferative activity and mechanism of action of DZ-3358, a novel pyrimidinyl pyrazole derivative.
    Iwahana M, Ochi Y, Ejima A.
    Anticancer Res; 2000 Feb 15; 20(2A):785-92. PubMed ID: 10810355
    [Abstract] [Full Text] [Related]

  • 17. Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole.
    Mooberry SL, Weiderhold KN, Dakshanamurthy S, Hamel E, Banner EJ, Kharlamova A, Hempel J, Gupton JT, Brown ML.
    Mol Pharmacol; 2007 Jul 15; 72(1):132-40. PubMed ID: 17456786
    [Abstract] [Full Text] [Related]

  • 18. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY.
    Cancer Res; 2004 Jul 01; 64(13):4621-8. PubMed ID: 15231674
    [Abstract] [Full Text] [Related]

  • 19. Novel multidrug resistance reversal agents.
    Berger D, Citarella R, Dutia M, Greenberger L, Hallett W, Paul R, Powell D.
    J Med Chem; 1999 Jun 17; 42(12):2145-61. PubMed ID: 10377220
    [Abstract] [Full Text] [Related]

  • 20. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
    Jiang JD, Denner L, Ling YH, Li JN, Davis A, Wang Y, Li Y, Roboz J, Wang LG, Perez-Soler R, Marcelli M, Bekesi G, Holland JF.
    Cancer Res; 2002 Nov 01; 62(21):6080-8. PubMed ID: 12414632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.